PE20170385A1 - Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo - Google Patents

Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo

Info

Publication number
PE20170385A1
PE20170385A1 PE2016002230A PE2016002230A PE20170385A1 PE 20170385 A1 PE20170385 A1 PE 20170385A1 PE 2016002230 A PE2016002230 A PE 2016002230A PE 2016002230 A PE2016002230 A PE 2016002230A PE 20170385 A1 PE20170385 A1 PE 20170385A1
Authority
PE
Peru
Prior art keywords
cyanopyrimidin
dihydropyrrolo
carbonitrile
triazine
oxo
Prior art date
Application number
PE2016002230A
Other languages
English (en)
Inventor
Carrera Francesc Carrera
Garcia Juan Bautista Perez
Juan Bernat Vidal
Coma Maria Carme Serra
Izquierdo Francisco Sanchez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20170385A1 publication Critical patent/PE20170385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invencion se refiere a nuevas sales de adicion, farmaceuticamente aceptables, de (S)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo con derivados de acido sulfonico en particular con acido metanosulfonico, acido naftaleno-2-sulfonico y acido paratoluenosulfonico, y a los solvatos farmaceuticamente aceptables de las mismas, y su uso como inhibidores de Fosfoinositido 3-quinasa (PI3K)
PE2016002230A 2014-05-27 2015-05-21 Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo PE20170385A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382192 2014-05-27
EP14382400 2014-10-17
EP14382401 2014-10-17

Publications (1)

Publication Number Publication Date
PE20170385A1 true PE20170385A1 (es) 2017-04-09

Family

ID=53269467

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002228A PE20170145A1 (es) 2014-05-27 2015-05-21 Combinacion
PE2016002230A PE20170385A1 (es) 2014-05-27 2015-05-21 Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016002228A PE20170145A1 (es) 2014-05-27 2015-05-21 Combinacion

Country Status (21)

Country Link
US (3) US20170189409A1 (es)
EP (3) EP3148585A1 (es)
JP (3) JP2017516799A (es)
KR (3) KR20170010369A (es)
CN (3) CN106414449A (es)
AU (3) AU2015266191A1 (es)
BR (1) BR112016024538A2 (es)
CA (3) CA2944611A1 (es)
CL (2) CL2016002970A1 (es)
CR (3) CR20160537A (es)
EA (3) EA201692437A1 (es)
IL (3) IL247073A0 (es)
MA (3) MA39828A (es)
MD (3) MD20160137A2 (es)
MX (3) MX2016014864A (es)
PE (2) PE20170145A1 (es)
PH (3) PH12016502256A1 (es)
SG (3) SG11201606763VA (es)
TW (3) TW201625260A (es)
UY (3) UY36151A (es)
WO (3) WO2015181055A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US10993947B2 (en) 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
GB201608797D0 (en) * 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
CN107456454A (zh) * 2016-06-06 2017-12-12 先声药业有限公司 一种预防或治疗炎性疾病的药物组合物
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
GB201708856D0 (en) * 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms
WO2019101853A1 (en) * 2017-11-23 2019-05-31 Piqur Therapeutics Ag Treatment of skin disorders
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
CN113440614A (zh) * 2020-03-26 2021-09-28 长沙晶易医药科技有限公司 一种用于治疗类风湿性关节炎的组合物及其应用
KR20230065591A (ko) * 2021-11-05 2023-05-12 연세대학교 산학협력단 피부-특이적 T 세포(skin-specific T cell)의 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023114369A2 (en) * 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of pi3k-delta inhibitors
TWI823476B (zh) * 2022-07-15 2023-11-21 中化合成生技股份有限公司 托法替尼檸檬酸鹽的製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123968A (zh) * 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
WO2007023186A1 (en) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
JP2012521994A (ja) * 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
MD20160137A2 (ro) 2017-05-31
PH12016502252A1 (en) 2017-02-06
MA39828A (fr) 2015-12-03
CA2941436A1 (en) 2015-12-03
IL247072A0 (en) 2016-09-29
MX2016014904A (es) 2017-02-28
CR20160536A (es) 2017-01-02
KR20170012236A (ko) 2017-02-02
EA201692435A1 (ru) 2017-04-28
JP2017516797A (ja) 2017-06-22
MX2016014861A (es) 2017-04-06
US20170158699A1 (en) 2017-06-08
CN107074862A (zh) 2017-08-18
SG11201607950SA (en) 2016-10-28
CR20160537A (es) 2017-03-17
CN106456777A (zh) 2017-02-22
MD20160138A2 (ro) 2017-05-31
BR112016024538A2 (pt) 2017-08-15
PH12016502255A1 (en) 2017-02-06
MA39829A (fr) 2015-12-03
AU2015266193A1 (en) 2016-09-15
US20170151264A1 (en) 2017-06-01
PE20170145A1 (es) 2017-03-10
MX2016014864A (es) 2017-04-06
PH12016502256A1 (en) 2017-02-06
CN106414449A (zh) 2017-02-15
UY36152A (es) 2016-01-08
CA2941429A1 (en) 2015-12-03
CA2944611A1 (en) 2015-12-03
EP3148585A1 (en) 2017-04-05
JP2017516798A (ja) 2017-06-22
EA201692436A1 (ru) 2017-04-28
SG11201606762PA (en) 2016-09-29
SG11201606763VA (en) 2016-09-29
AU2015266191A1 (en) 2016-09-15
UY36151A (es) 2016-01-08
TW201625259A (zh) 2016-07-16
IL247073A0 (en) 2016-09-29
TW201625260A (zh) 2016-07-16
EP3148999A1 (en) 2017-04-05
MA39827A (fr) 2015-12-03
WO2015181053A1 (en) 2015-12-03
EA201692437A1 (ru) 2017-04-28
TW201625258A (zh) 2016-07-16
KR20170010369A (ko) 2017-01-31
EP3148586A1 (en) 2017-04-05
CL2016002971A1 (es) 2017-02-17
AU2015266190A1 (en) 2016-10-20
CR20160538A (es) 2017-01-02
WO2015181052A1 (en) 2015-12-03
UY36153A (es) 2016-01-08
IL247901A0 (en) 2016-11-30
KR20170007760A (ko) 2017-01-20
JP2017516799A (ja) 2017-06-22
MD20160132A2 (ro) 2017-05-31
US20170189409A1 (en) 2017-07-06
WO2015181055A1 (en) 2015-12-03
CL2016002970A1 (es) 2017-02-10

Similar Documents

Publication Publication Date Title
PE20170385A1 (es) Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
GT201400196A (es) Compuestos de heterociclilo
SV2017005555A (es) Composiciones de acido obeticolico y metodos de uso
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20140460A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
ECSP13013009A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
CU20180019A7 (es) Derivados de heteroarilo como inhibidores de parp
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY34018A (es) Derivados glucósidos y usos de los mismos
DOP2019000290A (es) Inhibidores de quinasa y usos de los mismos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
CL2018003158A1 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2019008110A2 (es) Activador de nrf2
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
AR100620A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal